Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy
JACC: Heart Failure · 2025-05 · 13 (5) · 685-694
DOI: 10.1016/j.jchf.2025.03.017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JACC: Heart Failure, 2025-05. Verfasst von Jan M Griffin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical University of South Carolina, Charleston, South Carolina, USA. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Prealbumin. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NHLBI NIH HHS, NIH.
Abstract (Originalsprache)
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative cardiomyopathy that results from myocardial deposition of misfolded transthyretin (TTR) protein. The biology of amyloid formation has been elucidated resulting in several effective therapeutic strategies. Accordingly, the therapeutic landscape for ATTR-CM is rapidly evolving, with multiple disease-modifying therapies (DMTs) approved and others anticipated to be imminently available. Currently, DMT strategies involve either stabilization of TTR, thereby inhibiting misfolding, or reduction of hepatic TTR production, and antibodies ("depleters") that facilitate amyloid fibril removal are under development. In this review, available evidence is synthesized and expert experience provided to assist clinicians in the complex navigation of treatment selection and the role of advanced therapies (heart transplantation and left ventricular assist device), as well as to identify key areas for future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical University of South Carolina, Charleston, South Carolina, USA.
- University of Southwestern Medical Center, Dallas, Texas, USA.
- Boston Medical Center/Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.
- Oregon Health Sciences University, Portland, Oregon, USA.
- Cleveland Clinic, Cleveland, Ohio, USA.
- Columbia University Irving Medical Center, New York, New York, USA. Electronic address: msm10@cumc.columbia.edu.
Förderung
- NIA NIH HHS
- NHLBI NIH HHS
- NIH
Zitieren
APA
Griffin, J. M., Grodin, J. L., Ruberg, F. L., Masri, A., Hanna, M., & Maurer, M. S. (2025). Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy. JACC: Heart Failure, 13(5), 685-694. https://doi.org/10.1016/j.jchf.2025.03.017
Vancouver
Griffin JM, Grodin JL, Ruberg FL, Masri A, Hanna M, Maurer MS. Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy. JACC: Heart Failure. 2025;13(5):685-694. doi:10.1016/j.jchf.2025.03.017
BibTeX
@article{Griffin2025,
author = {Griffin, Jan M and Grodin, Justin L and Ruberg, Frederick L and Masri, Ahmad and Hanna, Mazen and Maurer, Mathew S},
title = {Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy},
journal = {JACC: Heart Failure},
year = {2025},
volume = {13},
number = {5},
pages = {685--694},
doi = {10.1016/j.jchf.2025.03.017}
}
EUVIMED